Abstract: This medicament characterized by containing an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein together or separately in combination with a pyrimidine drug, a platinum formulation, and an angiogenesis inhibitor is useful as a medicament for treatment and/or prevention of cancer in a cancer patient having a past history of another cancer treatment.
| # | Name | Date |
|---|---|---|
| 1 | 202337088084-STATEMENT OF UNDERTAKING (FORM 3) [22-12-2023(online)].pdf | 2023-12-22 |
| 2 | 202337088084-Sequence Listing in XML (WIPO ST26) [22-12-2023(online)].pdf | 2023-12-22 |
| 3 | 202337088084-Sequence Listing in txt [22-12-2023(online)].txt | 2023-12-22 |
| 4 | 202337088084-Sequence Listing in PDF [22-12-2023(online)].pdf | 2023-12-22 |
| 5 | 202337088084-PROOF OF RIGHT [22-12-2023(online)].pdf | 2023-12-22 |
| 6 | 202337088084-POWER OF AUTHORITY [22-12-2023(online)].pdf | 2023-12-22 |
| 7 | 202337088084-FORM 1 [22-12-2023(online)].pdf | 2023-12-22 |
| 8 | 202337088084-FIGURE OF ABSTRACT [22-12-2023(online)].pdf | 2023-12-22 |
| 9 | 202337088084-DRAWINGS [22-12-2023(online)].pdf | 2023-12-22 |
| 10 | 202337088084-DECLARATION OF INVENTORSHIP (FORM 5) [22-12-2023(online)].pdf | 2023-12-22 |
| 11 | 202337088084-COMPLETE SPECIFICATION [22-12-2023(online)].pdf | 2023-12-22 |
| 12 | 202337088084-certified copy of translation [22-12-2023(online)].pdf | 2023-12-22 |
| 13 | 202337088084-MARKED COPIES OF AMENDEMENTS [13-02-2024(online)].pdf | 2024-02-13 |
| 14 | 202337088084-FORM 13 [13-02-2024(online)].pdf | 2024-02-13 |
| 15 | 202337088084-AMMENDED DOCUMENTS [13-02-2024(online)].pdf | 2024-02-13 |
| 16 | 202337088084-FORM 3 [17-06-2024(online)].pdf | 2024-06-17 |
| 17 | 202337088084-MARKED COPIES OF AMENDEMENTS [22-05-2025(online)].pdf | 2025-05-22 |
| 18 | 202337088084-FORM 18 [22-05-2025(online)].pdf | 2025-05-22 |
| 19 | 202337088084-FORM 13 [22-05-2025(online)].pdf | 2025-05-22 |
| 20 | 202337088084-AMMENDED DOCUMENTS [22-05-2025(online)].pdf | 2025-05-22 |